Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF TECHNICAL OFFICER | February 25, 2025 | February 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,756 |
Ending reported balance
After 2025-02-27 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-02-25 · Sale · Disposed 9,300 · Balance 186,153 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2025-02-25 · Sale · Disposed 700 · Balance 185,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2025-02-26 · Sale · Disposed 9,400 · Balance 176,053 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2025-02-26 · Sale · Disposed 600 · Balance 175,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2025-02-27 · Sale · Disposed 1,597 · Balance 173,856 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2025-02-27 · Sale · Disposed 100 · Balance 173,756 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.
F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2020 Filed Feb 18, 2020 21:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,995 | $21.10 | $42,094.50 |
DisclosureSEC source: 0001179110-20-001750 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,428 F1 · shares: The reported disposition of 1,995 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,772 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001750 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,883 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001582 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,649 Underlying: Common Stock · 7,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,725 | $20.00 | $54,500.00 |
DisclosureSEC source: 0001179110-20-001582 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,651 F1 · shares: The reported disposition of 2,725 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001582 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 32,533 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001535 · edgar.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,533 Underlying: Common Stock · 32,533 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 69,174 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001179110-20-001535 · edgar.xml · derivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,174 Underlying: Common Stock · 69,174 shares Expires 2030-02-10 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock · Derivative | 11,559 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000992 · edgar.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,559 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 4,289 | $19.21 | $82,391.69 |
DisclosureSEC source: 0001179110-20-000992 · edgar.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,493 F1 · shares: The reported disposition of 4,289 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:24 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 11,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000992 · edgar.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.